LTF and hepatocellular carcinoma: In this case, the Lf-modified-liposomes specifically bind to LfR on the hepatoma cell’s surface, exhibiting sustained drug delivery and a reduced therapeutic dose, possibly avoiding the deleterious side effects associated with T3 treatment.